JFJordan FeldMD, MPHVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPHView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Session 2 Panel discussionView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela PaulsenView Video
MMMala MainiMD, PhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Antiviral effect of the RIG-I agonist, Inarigavir | Nezam AfdahlView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Session 3 Panel discussionView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for Modulating Adaptive Immunity | Robert ThimmeView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Full title: Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre BoonstraView Video
HJHarry JanssenMD, PhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What is the cure rate with current therapies? | Harry Janssen, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong ZhuView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew VaillantView Video
